Capmatinib
Sign in to save this workspacePrimary targets: C_MET · FDA status: FDA Approved
Selectivity scorecard
KISS
99.75
Gini
0.582
CATDS
0.046
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Capmatinib. Strongest target: C_MET at 99.5% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | C_MET | 99.5% | 0.5% |
| 2 | EGFR | 63.1% | 36.9% |
| 3 | ROS_ROS1 | 60.2% | 39.8% |
| 4 | JAK3 | 53.5% | 46.5% |
| 5 | RON_MST1R | 26.4% | 73.6% |
| 6 | MST3_STK24 | 22.2% | 77.8% |
| 7 | SRPK2 | 20.8% | 79.2% |
| 8 | HASPIN | 20.7% | 79.3% |
| 9 | AXL | 20.1% | 79.9% |
| 10 | MYLK4 | 19.7% | 80.3% |
| 11 | RIPK2 | 19.3% | 80.7% |
| 12 | PDGFRB | 17.9% | 82.1% |
| 13 | ERBB4_HER4 | 17.3% | 82.7% |
| 14 | EIF2AK2 | 17.0% | 83.0% |
| 15 | STK32B_YANK2 | 16.4% | 83.6% |
| 16 | ABL2_ARG | 15.9% | 84.1% |
| 17 | CAMKK2 | 15.8% | 84.2% |
| 18 | PKN3_PRK3 | 15.7% | 84.3% |
| 19 | PDK3_PDHK3 | 15.4% | 84.6% |
| 20 | CAMK1D | 15.1% | 84.9% |
Selectivity landscape
Where Capmatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Capmatinib.
Atlas insights for Capmatinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 697.17 | |
| ALLOGRAFT_REJECTION | 1539.33 | |
| ANDROGEN_RESPONSE | 859.75 | |
| ANGIOGENESIS | 352.81 | |
| APICAL_JUNCTION | 2059.82 | |
| APICAL_SURFACE | 251.42 | |
| APOPTOSIS | 1967.95 | |
| BILE_ACID_METABOLISM | 261.27 | |
| CHOLESTEROL_HOMEOSTASIS | 499.25 | |
| COAGULATION | 192.92 | |
| COMPLEMENT | 1373.27 | |
| DNA_REPAIR | 596.08 | |
| E2F_TARGETS | 1820.06 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 660.67 | |
| ESTROGEN_RESPONSE_EARLY | 1100.81 | |
| ESTROGEN_RESPONSE_LATE | 996.44 | |
| FATTY_ACID_METABOLISM | 135.79 | |
| G2M_CHECKPOINT | 1580.01 | |
| GLYCOLYSIS | 715.13 | |
| HEDGEHOG_SIGNALING | 288.61 | |
| HEME_METABOLISM | 510.03 | |
| HYPOXIA | 1202.85 | |
| IL2_STAT5_SIGNALING | 762.96 | |
| IL6_JAK_STAT3_SIGNALING | 1088.99 | |
| INFLAMMATORY_RESPONSE | 1305.48 | |
| INTERFERON_ALPHA_RESPONSE | 243.56 | |
| INTERFERON_GAMMA_RESPONSE | 1539.52 | |
| KRAS_SIGNALING_DN | 389.03 | |
| KRAS_SIGNALING_UP | 729.69 | |
| MITOTIC_SPINDLE | 1631.74 | |
| MTORC1_SIGNALING | 1023.05 | |
| MYC_TARGETS_V1 | 1079.09 | |
| MYC_TARGETS_V2 | 262.16 | |
| MYOGENESIS | 975.22 | |
| NOTCH_SIGNALING | 139.24 | |
| OXIDATIVE_PHOSPHORYLATION | 313.89 | |
| P53_PATHWAY | 1080.53 | |
| PANCREAS_BETA_CELLS | 140.52 | |
| PEROXISOME | 322.06 | |
| PI3K_AKT_MTOR_SIGNALING | 2052.36 | |
| PROTEIN_SECRETION | 612.42 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 154.43 | |
| SPERMATOGENESIS | 486.58 | |
| TGF_BETA_SIGNALING | 623.38 | |
| TNFA_SIGNALING_VIA_NFKB | 1503.62 | |
| UNFOLDED_PROTEIN_RESPONSE | 496.06 | |
| UV_RESPONSE_DN | 1175.44 | |
| UV_RESPONSE_UP | 1004.75 | |
| WNT_BETA_CATENIN_SIGNALING | 740.22 | |
| XENOBIOTIC_METABOLISM | 501.92 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.883 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.863 |
| SRR12202498 | — | 0.852 |
| SRR23303752 | — | 0.852 |
| aMVAC.P_005_TURBT_S223 | — | 0.852 |
Annotations
Sign in to read and post annotations.
Loading…